journal
https://read.qxmd.com/read/37010785/surgery-in-the-era-of-immunotherapy-for-advanced-head-and-neck-non-melanoma-skin-cancer
#21
REVIEW
Alice Lin, Cecelia E Schmalbach
PURPOSE OF REVIEW: Surgery remains the mainstay of treatment for non-melanoma skin cancer (NMSC). Immunotherapy (IO) has emerged as an alternative option. This review provides a contemporary summary of how to incorporate IO into the management of advanced NMSC. Evidence-based outcomes and recent clinical trials are provided with emphasis on the three most common NMSC diagnoses: cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), and merkel cell carcinoma (MCC). RECENT FINDINGS: Surgical resection while preserving form and function remains the standard of care for the majority of NMSCs...
April 3, 2023: Current Oncology Reports
https://read.qxmd.com/read/37004702/the-latest-option-nivolumab-and-relatlimab-in-advanced-melanoma
#22
REVIEW
Lea Jessica Albrecht, Elisabeth Livingstone, Lisa Zimmer, Dirk Schadendorf
PURPOSE OF REVIEW: Dual immune checkpoint inhibition with ipilimumab plus nivolumab is currently the most effective, but also by far the most toxic treatment for advanced melanoma. Therefore, other combination partners that also lead to high and long-lasting responses but cause fewer adverse events were explored. RECENT FINDINGS: Relatlimab, a LAG-3 blocking antibody, was investigated in combination with nivolumab in a phase 2/3 randomized double-blind trial (RELATIVITY-047) and could demonstrate significantly improved progression-free survival in treatment-naive advanced melanoma patients compared with nivolumab monotherapy...
April 1, 2023: Current Oncology Reports
https://read.qxmd.com/read/37004701/surgical-management-of-the-primary-tumor-in-stage-iv-small-intestinal-neuroendocrine-tumors-to-operate-or-not-to-operate-that-is-the-question
#23
REVIEW
Kim Dijke, Koert F D Kuhlmann, Sonja Levy, Margot E T Tesselaar
PURPOSE OF REVIEW: Small intestinal neuroendocrine tumors (SI-NET) are rare tumors, often with distant metastases at diagnosis. The objective of this review is to provide an overview of the latest literature regarding surgical management of the primary tumor in stage IV SI-NET. RECENT FINDINGS: Primary tumor resection (PTR) seems to be associated with improved survival in patients with stage IV SI-NET, independent of treatment of distant metastases. A watch and wait approach of the primary tumor increases the risk of needing an emergency resection...
April 1, 2023: Current Oncology Reports
https://read.qxmd.com/read/37004700/advances-in-endocrine-therapy-for-hormone-receptor-positive-advanced-breast-cancer
#24
REVIEW
Sharvina Ziyeh, Lauren Wong, Reva K Basho
PURPOSE OF REVIEW: To provide an overview of the current management of hormone receptor-positive (HR +) advanced breast cancer as well as highlight ongoing clinical investigation and novel therapies in development. RECENT FINDINGS: CDK4/6 inhibition plus endocrine therapy is standard front-line therapy for HR + advanced breast cancer. Continuation of CDK4/6 inhibitors in combination with alternative endocrine therapy has been evaluated in the second-line setting...
April 1, 2023: Current Oncology Reports
https://read.qxmd.com/read/37000340/recent-advances-in-melanoma-diagnosis-and-prognosis-using-machine-learning-methods
#25
REVIEW
Sarah Grossarth, Dominique Mosley, Christopher Madden, Jacqueline Ike, Isabelle Smith, Yuankai Huo, Lee Wheless
PURPOSE OF REVIEW: The purpose was to summarize the current role and state of artificial intelligence and machine learning in the diagnosis and management of melanoma. RECENT FINDINGS: Deep learning algorithms can identify melanoma from clinical, dermoscopic, and whole slide pathology images with increasing accuracy. Efforts to provide more granular annotation to datasets and to identify new predictors are ongoing. There have been many incremental advances in both melanoma diagnostics and prognostic tools using artificial intelligence and machine learning...
March 31, 2023: Current Oncology Reports
https://read.qxmd.com/read/36995534/sequencing-targeted-and-immune-therapy-in-braf-mutant-melanoma-lessons-learned
#26
REVIEW
Claudia Trojaniello, Francesca Sparano, Eleonora Cioli, Paolo Antonio Ascierto
PURPOSE OF REVIEW: The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence on the efficacy and safety of sequential immunotherapy with targeted therapy in patients with BRAF-mutated melanoma. It discusses criteria for the use of available options in clinical practice. RECENT FINDINGS: Targeted therapy provides rapid disease control in a relatively high proportion of patients, although the development of secondary resistance limits the duration of responses; in contrast, immunotherapy may induce slow but more durable responses in a subset of patients...
June 2023: Current Oncology Reports
https://read.qxmd.com/read/36995533/addressing-social-determinants-of-health-to-reduce-disparities-among-individuals-with-cancer-insights-for-rehabilitation-professionals
#27
REVIEW
Ekta Gupta, Charles H Mitchell, An Ngo-Huang, Radhika Manne, Nicole L Stout
PURPOSE OF REVIEW: This report aims to provide a framework for cancer rehabilitation professionals to assess social determinants of health in individuals with cancer and discuss strategies that can be implemented in practice to overcome barriers to care. RECENT FINDINGS: There has been an increased focus in improving patient conditions that can affect access to cancer rehabilitation. Along with government and world health organization initiatives, healthcare professionals and institutions continue to work towards decreasing disparities...
March 30, 2023: Current Oncology Reports
https://read.qxmd.com/read/36988735/chemotherapy-in-cutaneous-melanoma-is-there-still-a-role
#28
REVIEW
James P Pham, Anthony M Joshua, Ines P da Silva, Reinhard Dummer, Simone M Goldinger
PURPOSE OF REVIEW: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined. RECENT FINDINGS: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies...
March 29, 2023: Current Oncology Reports
https://read.qxmd.com/read/36976462/clinical-trials-in-the-brain-tumour-population-challenges-and-strategies-for-the-future
#29
REVIEW
Hui Kong Gan, Bryan W Day, Rosemary Harrup, Terrance G Johns, Zarnie Lwin, Andrew Mark Scott, Hao-Wen Sim, Eng-Siew Koh
PURPOSE OF REVIEW: This review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years. RECENT FINDINGS: Several key strategies have been proposed by leading groups to address these and improve patient outcomes. Better preclinical testing using more sophisticated and clinically relevant models is needed...
March 28, 2023: Current Oncology Reports
https://read.qxmd.com/read/36976461/allogeneic-hematopoietic-stem-cell-transplant-for-diffuse-large-b-cell-lymphoma-evolving-role-in-the-era-of-car-t-cell-therapy
#30
REVIEW
Talal Hilal, Luke J Mountjoy
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults. Although curable in the majority of cases, a substantial portion of patients will experience disease relapse and will die from their lymphoma. This review is aimed at summarizing the role of allogeneic hematopoietic stem cell transplant (allo-HSCT) in patients with relapsed DLBCL with a focus on its role in the era of CAR T-cell therapy RECENT FINDINGS: Allo-HSCT is primarily reserved for patients who experience disease progression or relapse after CAR T-cell therapy, largely due to the high non-relapse mortality (NRM) associated with the procedure...
March 28, 2023: Current Oncology Reports
https://read.qxmd.com/read/36943555/emerging-therapies-for-transthyretin-amyloidosis
#31
REVIEW
Melissa R Tsoi, Jeffrey H Lin, Ayan R Patel
PURPOSE OF REVIEW: This review provides an overview of the available therapies for treating neuropathic and/or cardiac manifestations of transthyretin amyloidosis (ATTR), as well as investigational therapeutic agents in ongoing clinical trials. We discuss additional emergent approaches towards thwarting this life-threatening disease that until recently was considered virtually untreatable. RECENT FINDINGS: Advances in noninvasive diagnostic methods for detecting ATTR have facilitated easier diagnosis and detection at an earlier stage of disease when therapeutic interventions are likely to be more effective...
March 21, 2023: Current Oncology Reports
https://read.qxmd.com/read/36939963/integrative-medicine-for-ovarian-cancer
#32
REVIEW
Eran Ben-Arye, Ofer Lavie, Wolfgang Heyl, Lois Ramondetta, Tara Berman, Noah Samuels
PURPOSE OF REVIEW: Integrative oncology (IO) services provide a wide range of complementary medicine therapies, many of which can augment the beneficial effects of conventional supportive and palliative care for patients with ovarian cancer. This study aims to assess the current state of integrative oncology research in ovarian cancer care. RECENT FINDINGS: We review the clinical research both supporting the effectiveness of leading IO modalities in ovarian cancer care as well as addressing potential safety-related concerns...
March 20, 2023: Current Oncology Reports
https://read.qxmd.com/read/36933171/advances-in-targeted-therapy-for-neurofibromatosis-type-2-nf2-associated-vestibular-schwannomas
#33
REVIEW
Evan C Cumpston, Steven D Rhodes, Charles W Yates
PURPOSE OF REVIEW: Neurofibromatosis 2 (NF2) is an autosomal-dominant genetic disorder characterized by bilateral vestibular schwannomas (VS), meningiomas, ependymomas, spinal and peripheral schwannomas, optic gliomas, and juvenile cataracts. Ongoing studies provide new insight into the role of the NF2 gene and merlin in VS tumorigenesis. RECENT FINDINGS: As NF2 tumor biology becomes increasingly understood, therapeutics targeting specific molecular pathways have been developed and evaluated in preclinical and clinical studies...
March 18, 2023: Current Oncology Reports
https://read.qxmd.com/read/36920638/axl-inhibitors-status-of-clinical-development
#34
REVIEW
Sheena Bhalla, David E Gerber
PURPOSE OF REVIEW: The AXL signaling pathway is associated with tumor growth as well as poor prognosis in cancer. Here, we highlight recent strategies for targeting AXL in the treatment of solid and hematological malignancies. RECENT FINDINGS: AXL is a key player in survival, metastasis, and therapeutic resistance in many cancers. A range of AXL-targeted therapies, including tyrosine kinase inhibitors, monoclonal antibodies, antibody-drug conjugates, and soluble receptors, have entered clinical development...
March 15, 2023: Current Oncology Reports
https://read.qxmd.com/read/36920637/clonal-hematopoiesis-and-the-heart-a-toxic-relationship
#35
REVIEW
Jeffrey L Jensen, Saumya Easaw, Travis Anderson, Yash Varma, Jiandong Zhang, Brian C Jensen, Catherine C Coombs
PURPOSE OF REVIEW: Clonal hematopoiesis (CH) refers to the expansion of hematopoietic stem cell clones and their cellular progeny due to somatic mutations, mosaic chromosomal alterations (mCAs), or copy number variants which naturally accumulate with age. CH has been linked to increased risk of blood cancers, but CH has also been linked to adverse cardiovascular outcomes. RECENT FINDINGS: A combination of clinical outcome studies and mouse models have offered strong evidence that CH mutations either correlate with or cause atherosclerosis, diabetes mellitus, chronic kidney disease, heart failure, pulmonary hypertension, aortic aneurysm, myocardial infarction, stroke, aortic stenosis, poor outcomes following transcatheter aortic valve replacement (TAVR) or orthotopic heart transplant, death or need of renal replacement therapy secondary to cardiogenic shock, death from cardiovascular causes at large, and enhance anthracycline cardiac toxicity...
March 15, 2023: Current Oncology Reports
https://read.qxmd.com/read/36881215/management-of-recurrent-hpv-positive-oropharyngeal-squamous-cell-carcinoma-a-contemporary-review
#36
REVIEW
Sam Dowthwaite, James Jackson, Marcin Dzienis, Eric Khoo, Mathew Cronin, Emily Guazzo
PURPOSE OF REVIEW: To review the impact of contemporary treatment strategies on salvage outcomes in patients with recurrent human papilloma virus-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC). RECENT FINDINGS: Secondary to HPV, changes in disease biology have impacted primary treatments and subsequent approaches to patients with recurrence. With treatment strategies more inclusive of upfront surgery, the characteristics of patients with recurrence HPV + OPSCC have been further redefined...
March 7, 2023: Current Oncology Reports
https://read.qxmd.com/read/36867377/cardiovascular-risks-in-testicular-cancer-assessment-prevention-and-treatment
#37
REVIEW
Suparna C Clasen, Chunkit Fung, Howard D Sesso, Lois B Travis
PURPOSE OF REVIEW: Testicular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) including myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS)...
March 3, 2023: Current Oncology Reports
https://read.qxmd.com/read/36862337/molecular-profiling-in-early-er%C3%A2-%C3%A2-breast-cancer-to-aid-systemic-therapy-decisions
#38
REVIEW
Oleg Gluz, Monika Graeser
PURPOSE OF REVIEW: Clinical decisions for (neo)adjuvant treatment in early breast cancer (eBC) have been based mostly on clinical factors over the last decades. We have reviewed development and validation of such assays in the HR + /HER2 eBC and discuss possible future directions in this field. RECENT FINDINGS: Increasing knowledge about the biology of hormone-sensitive eBC, based on the precise and reproducible multigene expression analysis, has led to a significant change in the treatment pathways and reduction of overtreatment in particular by chemotherapy in HR + /HER2 eBC with up to 3 positive lymph nodes based on results from several retrospective-prospective trials used several genomic assays and in particular prospective trials (TAILORx, RxPonder, MINDACT, and ADAPT used OncotypeDX® and Mammaprint®)...
March 2, 2023: Current Oncology Reports
https://read.qxmd.com/read/37000341/current-status-of-predictive-biomarker-development-in-metastatic-renal-cell-carcinoma
#39
REVIEW
Giuseppe Fotia, Marco Stellato, Valentina Guadalupi, Pierangela Sepe, Melanie Claps, Patrizia Giannatempo, Achille Bottiglieri, Alessandro Rametta, Ida Taglialatela, Chiara Vela, Giuseppe Procopio, Elena Verzoni
PURPOSE OF REVIEW: In this review, we analyze the current state of research in development of new biomarkers that may be useful in managing metastatic renal cell carcinoma (mRCC) setting. RECENT FINDINGS: Combining tumor-based biomarkers (gene expression profile) and blood-based biomarkers (ctDNA, cytokines) would be helpful in acquiring information regarding RCC and might be significant in the decision-making process. Renal cell carcinoma (RCC) is the sixth most frequently diagnosed neoplasm in men and tithe in women, making it responsible for 5% and 3% of all diagnosed cancers respectively...
June 2023: Current Oncology Reports
https://read.qxmd.com/read/36995535/medicinal-mushroom-supplements-in-cancer-a-systematic-review-of-clinical-studies
#40
REVIEW
Santhosshi Narayanan, Aline Rozman de Mores, Lorenzo Cohen, Mohammed Moustapha Anwar, Felippe Lazar, Rachel Hicklen, Gabriel Lopez, Peiying Yang, Eduardo Bruera
PURPOSE OF REVIEW: Patients seek clinical guidance on mushroom supplements that can be given alongside conventional treatments, but most research on such fungi has been preclinical. The current systematic review focused on clinical studies of mushrooms in cancer care conducted in the past 10 years. We searched Medline (Ovid), Embase (Ovid), Scopus (Wiley), and Cochrane Library to identify all mushroom studies conducted in humans published from January 2010 through December 2020. Two authors independently assessed papers for inclusion...
June 2023: Current Oncology Reports
journal
journal
34702
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.